These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34152584)

  • 1. Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar.
    Courville J; Nastoupil L; Kaila N; Kelton J; Zhang J; Alcasid A; Nava-Parada P
    BioDrugs; 2021 Jul; 35(4):459-468. PubMed ID: 34152584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
    Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
    BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.
    Muntañola A; Arguiñano-Pérez JM; Dávila J; de Villambrosia SG; Carpio C; Jiménez-Ubieto A; Salar A;
    Clin Transl Sci; 2023 Feb; 16(2):305-312. PubMed ID: 36385738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
    Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
    Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
    Tony HP; Krüger K; Cohen SB; Schulze-Koops H; Kivitz AJ; Jeka S; Vereckei E; Cen L; Kring L; Kollins D
    Arthritis Care Res (Hoboken); 2019 Jan; 71(1):88-94. PubMed ID: 30295429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial.
    Park W; Božić-Majstorović L; Milakovic D; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Molina FFC; Shesternya P; Miranda P; Medina-Rodriguez FG; Wiland P; Jeka S; Chavez-Corrales J; Garmish O; Linde T; Rekalov D; Hrycaj P; Krause A; Fomina N; Piura O; Abello-Banfi M; Suh CH; Shim SC; Lee SJ; Lee SY; Kim SH; Yoo DH
    MAbs; 2018; 10(6):934-943. PubMed ID: 30010481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).
    Ryan AM; Sokolowski SA; Ng CK; Shirai N; Collinge M; Shen AC; Arrington J; Radi Z; Cummings TR; Ploch SA; Stephenson SA; Tripathi NK; Hurst SI; Finch GL; Leach MW
    Toxicol Pathol; 2014 Oct; 42(7):1069-81. PubMed ID: 24604381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
    Shim SC; Božić-Majstorović L; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Cons Molina FF; Medina-Rodriguez FG; Miranda P; Shesternya P; Chavez-Corrales J; Wiland P; Jeka S; Garmish O; Hrycaj P; Fomina N; Park W; Suh CH; Lee SJ; Lee SY; Bae YJ; Yoo DH
    Rheumatology (Oxford); 2019 Dec; 58(12):2193-2202. PubMed ID: 31184752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma.
    Tsutsumi D; Hayama T; Miura K; Uchiike A; Tsuboi S; Otsuka S; Hatta Y; Kishikawa Y
    Int J Clin Pharm; 2022 Apr; 44(2):366-373. PubMed ID: 34894347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases.
    Oomen I; Nassar-Sheikh Rashid A; Bouts AHM; Gouw SC; Kuijpers TW; Rispens T; de Vries A; Wolbink G; van den Berg JM; Schonenberg-Meinema D
    Clin Exp Rheumatol; 2022 Jan; 40(1):183-190. PubMed ID: 34251329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
    Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
    BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience.
    Olszewska-Szopa M; Ożańska A; Ożański T; Rybka J; Wróbel T
    Leuk Lymphoma; 2024 Jan; 65(1):55-61. PubMed ID: 37888870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
    Bishton M; Marshall S; Harchowal J; Salles G; Golfier C; Tucci A; Fernández AR; Sanchez Blanco JJ; Bocchia M; Kim S; Lee YN; Zinzani PL
    Hematol Oncol; 2022 Aug; 40(3):370-380. PubMed ID: 35168291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
    Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
    Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion-related reactions to rituximab: frequency, mechanisms and predictors.
    Paul F; Cartron G
    Expert Rev Clin Immunol; 2019 Apr; 15(4):383-389. PubMed ID: 30580638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
    Rioufol C; Salles G
    Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
    Coiffier B
    Expert Rev Clin Pharmacol; 2017 Sep; 10(9):923-933. PubMed ID: 28766389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.
    Hayama T; Miura K; Uchiike A; Nakagawa M; Tsutsumi D; Sakagami M; Yoshida Y; Takei M
    Int J Clin Pharm; 2017 Apr; 39(2):380-385. PubMed ID: 28144804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.
    Hong J; Kim JY; Ahn HK; Lee SM; Sym SJ; Park J; Cho EK; Ahn JY; Park S; Lee SP; Shin DB; Lee JH
    Support Care Cancer; 2013 Apr; 21(4):1145-52. PubMed ID: 23111943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.
    Smolen JS; Cohen SB; Tony HP; Scheinberg M; Kivitz A; Balanescu A; Gomez-Reino J; Cen L; Poetzl J; Shisha T; Kollins D
    Rheumatology (Oxford); 2021 Jan; 60(1):256-262. PubMed ID: 32699904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.